Arbutus Biopharma CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have updated their Schedule 13G filing to reflect their beneficial ownership of Arbutus Biopharma Corp. common shares.
NASDAQ
Two Seas Capital LP and Sina Toussi have reported a 9.4% beneficial ownership stake in Arbutus Biopharma Corporation.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., reported beneficial ownership of 13.5% of Arbutus Biopharma Corp's common shares.
NASDAQ
Two Seas Capital LP and its affiliates have disclosed a 5.4% beneficial ownership in Arbutus Biopharma Corporation as of June 30, 2025, held for investment purposes.
NASDAQ
SCHEDULE 13G/A: Morgan Stanley Amends Stake in Arbutus Biopharma, Disclosing 11.4% Beneficial Ownership
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed an amended Schedule 13G, revealing a combined beneficial ownership of 11.4% in Arbutus Biopharma Corp as of December 31, 2024.